QUIDE Drug Patent Profile
✉ Email this page to a colleague
When do Quide patents expire, and when can generic versions of Quide launch?
Quide is a drug marketed by Dow Pharm and is included in one NDA.
The generic ingredient in QUIDE is piperacetazine. There is one drug master file entry for this compound. Additional details are available on the piperacetazine profile page.
Summary for QUIDE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 43 |
Patent Applications: | 889 |
DailyMed Link: | QUIDE at DailyMed |
US Patents and Regulatory Information for QUIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dow Pharm | QUIDE | piperacetazine | TABLET;ORAL | 013615-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Dow Pharm | QUIDE | piperacetazine | TABLET;ORAL | 013615-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |